- Tilray Brands (TSX:TLRY), a cannabis stock with operations in over 20 countries, is announcing that subsidiary Aphria RX GmbH has received a cannabis trading license in Germany
- The German cannabis market is expected to grow from C$1.79 billion in 2024 to C$6.88 billion by 2034
- Tilray is a leading global cannabis lifestyle and consumer packaged goods company supporting more than 20 brands with operations in Canada, the United States, Europe, Australia and Latin America
- Tilray stock has given back 21.45 per cent year-over-year and 86.77 per cent since inception in 2021
Tilray Brands (TSX:TLRY), a cannabis stock with operations in more than 20 countries, is announcing that subsidiary Aphria RX GmbH has received a cannabis trading license in Germany.
After the award of a cultivation license just last week, Aphria RX will now be able to take full advantage of MedCanG, Germany’s cannabis act, by:
…
